Publications by authors named "Samia Kada Mohammed"
Background: HER2-positive (HER2 +) invasive lobular breast cancer (ILC) is rare and poorly characterised. In particular, patient outcomes compared to those associated with HER2 + invasive ductal cancer (IDC) and HER2-negative (HER2 -) ILC, as well as the benefits of anti-HER2 therapy, are not well established.
Methods: We analysed the data from the Côte d'Or Registry of Breast and Gynaecological Cancers (France) for all patients diagnosed with early-stage HER2 + ILC (62 cases), HER2 + IDC (833 cases) and HER2 - ILC (685 cases) between 1998 and 2015 to compare overall and disease-free survival (OS and DFS) between these groups in correlation with anti-HER2 therapy.
Article Synopsis
- The study investigates the prognosis of local invasive recurrence (LIR) in breast cancer patients with a history of carcinoma in situ (CIS) compared to those with de novo invasive breast cancer and LIR after primary invasive breast cancer.
- Data was collected from a breast cancer registry over several years, analyzing outcomes such as overall survival (OS) and distant relapse-free survival (D-RFS) among matched patient groups.
- Results indicate that there are no significant differences in survival outcomes between patients with LIR after CIS and those with other breast cancer types, suggesting that LIR after CIS does not negatively affect survival.